Number of Participants Who Experienced a Medically Attended Adverse Event (MAAE) During the Active Treatment Period;Number of Participants Who Experienced an Unsolicited Treatment-emergent Adverse Event (TEAE) During the Active Treatment Period;Number of Participants Who Experienced a Solicited Symptom of Reactogenicity;Severity of MAAEs During the Active Treatment Period;Severity of Solicited Symptoms of Reactogenicity;Severity of Unsolicited TEAEs During the Active Treatment Period

Number of Participants Who Experienced a Medically Attended Adverse Event (MAAE) During the Active Treatment Period;Number of Participants Who Experienced an Unsolicited Treatment-emergent Adverse Event (TEAE) During the Active Treatment Period;Number of Participants Who Experienced a Solicited Symptom of Reactogenicity;Severity of MAAEs During the Active Treatment Period;Severity of Solicited Symptoms of Reactogenicity;Severity of Unsolicited TEAEs During the Active Treatment Period

Rate of Solicited Symptoms of Reactogenicity Collected via a Diary Card (Part 1 and Part 2);Rate of Solicited Symptoms of Reactogenicity Collected via a Diary Card (Part 1 and Part 2);Rate of Unsolicited Adverse Events (Part 1 and Part 2);Rate of Unsolicited Adverse Events (Part 1 and Part 2);Serious Adverse Events (SAEs) and Medically Attended Adverse Events (MAAEs)

Rate of Solicited Symptoms of Reactogenicity Collected via a Diary Card (Part 1 and Part 2);Rate of Solicited Symptoms of Reactogenicity Collected via a Diary Card (Part 1 and Part 2);Rate of Unsolicited Adverse Events (Part 1 and Part 2);Rate of Unsolicited Adverse Events (Part 1 and Part 2);Serious Adverse Events (SAEs) and Medically Attended Adverse Events (MAAEs)